Last updated September 4, 2026
Key finding
No significant differences were found between the groups in terms of NRS (P = 0.787)
This study evaluated the efficacy and safety of nanocurcumin supplementation in patients with diabetic peripheral neuropathy, finding no significant differences between the treatment and placebo groups.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of nanocurcumin supplementation in patients with diabetic peripheral neuropathy, finding no significant differences between the treatment and placebo groups.
Understanding the effectiveness of new treatments like nanocurcumin is crucial for managing diabetic peripheral neuropathy. This study's findings suggest that nanocurcumin may not be a viable option for improving symptoms in affected patients, guiding clinicians in treatment decisions.
Limited sample size may affect generalizability Short duration of 16 weeks may not capture long-term effects Lack of significant findings raises questions about the intervention's effectiveness
Published in
Publication details and source links for this paper.
Asieh M, Hamid RR, Hadis G, et al. Efficacy and safety of nanocurcumin supplementation in patients with diabetic peripheral neuropathy: a randomized controlled trial. Nutrition Journal. 2025;24:115. doi:10.1186/s12937-025-01184-8
No significant difference in pain severity (NRS) between groups (P = 0.787)
No significant difference in Neuropathy Disability Score (NDS) (P = 0.576)
No significant difference in fasting blood sugar levels after 16 weeks (P = 0.599)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Nanocurcumin and AST, Alanine transaminase levels at 12 months, C-reactive protein, and 11 more.
This study contributes evidence to
Primary intervention
Nanocurcumin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
14
Evidence pairs
1313
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Nanocurcumin → Alanine transaminase levels at 12 months
Nanocurcumin → Alanine transaminase levels at 12 months
Nanocurcumin → Change in liver enzymes (GGT)
Nanocurcumin → Change in liver enzymes (GGT)
Nanocurcumin → Change in Michigan Neuropathy Screening Instrument score
Nanocurcumin → Change in Michigan Neuropathy Screening Instrument score
Nanocurcumin → Fasting blood sugar (FBS)
Nanocurcumin → Fasting blood sugar (FBS)
Nanocurcumin → Neuropathic pain severity
Nanocurcumin → Neuropathic pain severity
Nanocurcumin → Neuropathy Disability Score (NDS)
Nanocurcumin → Neuropathy Disability Score (NDS)
Nanocurcumin → Very-low-density lipoprotein cholesterol
Nanocurcumin → Very-low-density lipoprotein cholesterol
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Nanocurcumin and Alanine transaminase levels at 12 months, Nanocurcumin and AST.
This study contributes to the evidence on the following intervention-outcome relationships.
Supplements
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies measuring Alanine transaminase levels at 12 months
Measures Alanine transaminase levels at 12 months as a key outcome.
All studies measuring AST
Measures AST as a key outcome.
All studies on Nanocurcumin
Contributes to Nanocurcumin evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Current evidence does not show a clear benefit of Nanocurcumin for ast.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
AST
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Nanocurcumin for alanine transaminase levels at 12 months.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Alanine transaminase levels at 12 months
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Nanocurcumin for c-reactive protein.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
C-reactive protein
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Nanocurcumin for change in michigan neuropathy screening instrument score.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in Michigan Neuropathy Screening Instrument score
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
